Back to Search
Start Over
Comparison of Drug-coated Balloons versus Bare Metal Stents in Patients with Femoropopliteal Arterial Disease.
- Source :
-
Journal of the American College of Cardiology (JACC) . Jan2023, Vol. 81 Issue 3, p237-249. 13p. - Publication Year :
- 2023
-
Abstract
- <bold>Background: </bold>Endovascular treatment of femoropopliteal artery disease has shifted toward drug-coated balloons (DCB). However, limited data are available regarding the safety and efficacy of DCB vs bare-metal stents (BMS).<bold>Objectives: </bold>To compare DCB vs BMS outcomes in a propensity-adjusted, pooled analysis of 4 prospective, multicenter trials.<bold>Methods: </bold>Patient-level data were pooled from 4 prospective, multicenter studies: the IN.PACT SFA I/II and IN.PACT SFA Japan randomized controlled DCB trials and the Complete SE and DURABILITY II single-arm BMS studies. Outcomes were compared using inverse probability of treatment weighting (IPTW). Clinical endpoints were 12-month primary patency, freedom from 36-month clinically driven target lesion revascularization, and cumulative 36-month major adverse events (MAE).<bold>Results: </bold>The primary analysis included 771 patients (288 DCB, 483 BMS). IPTW-adjusted demographic, baseline lesion, and procedural characteristics were matched between groups. The adjusted mean lesion length was 8.1 ± 4.7 cm DCB and 7.9 ± 4.5 cm BMS. The IPTW-adjusted Kaplan-Meier estimates of 12-month primary patency (90.4% DCB, 80.9% BMS, P = 0.007), freedom from 36-month clinically driven target lesion revascularization (85.6% DCB, 73.7% BMS, P = 0.001), and cumulative incidence of 36-month MAE (25.3% DCB, 38.8% BMS, P < 0.001) favored DCB. There were no statistically significant differences observed in all-cause mortality, target limb major amputation, or thrombosis through 36 months.<bold>Conclusions: </bold>In a patient-level, IPTW-adjusted pooled analysis of prospective, multicenter pivotal studies, DCB demonstrated significantly higher patency, lower revascularization and MAE rates, and no statistically significant differences in mortality, amputation, or thrombosis versus BMS. This analysis supports DCB use vs BMS in moderately complex femoropopliteal lesions amenable to both treatments. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ARTERIAL diseases
*ENDOVASCULAR surgery
*PERIPHERAL vascular diseases
*MORTALITY
Subjects
Details
- Language :
- English
- ISSN :
- 07351097
- Volume :
- 81
- Issue :
- 3
- Database :
- Academic Search Index
- Journal :
- Journal of the American College of Cardiology (JACC)
- Publication Type :
- Academic Journal
- Accession number :
- 161171944
- Full Text :
- https://doi.org/10.1016/j.jacc.2022.10.016